{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T05:02:27Z","timestamp":1793422947103,"version":"4.5.0"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","gynecologiconcology-online.net","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.ygyno.2024.02.002","type":"journal-article","created":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T06:21:26Z","timestamp":1709706086000},"page":"245-253","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"special_numbering":"C","title":["2023 FIGO staging system for endometrial cancer: The evolution of the revolution"],"prefix":"10.1016","volume":"184","author":[{"given":"David","family":"Gaffney","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Matias-Guiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Mutch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Scambia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carien","family":"Creutzberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Fotopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan S.","family":"Berek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Concin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ygyno.2024.02.002_bb0005","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ijgo.2009.02.012","article-title":"Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium","volume":"105","author":"Pecorelli","year":"2009","journal-title":"Int. J. Gynaecol. Obstet."},{"issue":"18","key":"10.1016\/j.ygyno.2024.02.002_bb0010","doi-asserted-by":"crossref","first-page":"4231","DOI":"10.1002\/cncr.26030","article-title":"Does the revised International Federation of Gynecology and Obstetrics staging system for endometrial cancer lead to increased discrimination in patient outcomes?","volume":"117","author":"Cooke","year":"2011","journal-title":"Cancer."},{"issue":"7447","key":"10.1016\/j.ygyno.2024.02.002_bb0015","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Cancer Genome Atlas Research N","year":"2013","journal-title":"Nature."},{"issue":"29","key":"10.1016\/j.ygyno.2024.02.002_bb0020","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1200\/JCO.20.00549","article-title":"Molecular classification of the PORTEC-3 trial for high-risk endometrial Cancer: impact on prognosis and benefit from adjuvant therapy","volume":"38","author":"Leon-Castillo","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2024.02.002_bb0025","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1002\/path.5373","article-title":"Clinicopathological and molecular characterisation of \u2018multiple-classifier\u2019 endometrial carcinomas","volume":"250","author":"Leon-Castillo","year":"2020","journal-title":"J. Pathol."},{"issue":"1","key":"10.1016\/j.ygyno.2024.02.002_bb0030","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ygyno.2016.12.015","article-title":"Molecular approaches for classifying endometrial carcinoma","volume":"145","author":"Piulats","year":"2017","journal-title":"Gynecol. Oncol."},{"issue":"16","key":"10.1016\/j.ygyno.2024.02.002_bb0035","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1158\/1078-0432.CCR-15-2878","article-title":"Improved risk assessment by integrating molecular and Clinicopathological factors in early-stage endometrial Cancer-combined analysis of the PORTEC cohorts","volume":"22","author":"Stelloo","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.ygyno.2024.02.002_bb0040","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/cncr.30496","article-title":"Confirmation of ProMisE: a simple, genomics-based clinical classifier for endometrial cancer","volume":"123","author":"Talhouk","year":"2017","journal-title":"Cancer."},{"issue":"1","key":"10.1016\/j.ygyno.2024.02.002_bb0045","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/his.14015","article-title":"Incorporation of molecular characteristics into endometrial cancer management","volume":"76","author":"Vermij","year":"2020","journal-title":"Histopathology."},{"issue":"27","key":"10.1016\/j.ygyno.2024.02.002_bb0050","doi-asserted-by":"crossref","first-page":"4369","DOI":"10.1200\/JCO.23.00062","article-title":"Molecular classification predicts response to radiotherapy in the randomized PORTEC-1 and PORTEC-2 trials for early-stage Endometrioid endometrial cancer","volume":"41","author":"Horeweg","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2024.02.002_bb0055","article-title":"Risk stratification of stage I grade 3 Endometrioid endometrial carcinoma in the era of molecular classification","volume":"6","author":"Zammarrelli","year":"2022","journal-title":"JCO Precis. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2024.02.002_bb0060","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/ijgo.14923","article-title":"FIGO staging of endometrial cancer: 2023","volume":"162","author":"Berek","year":"2023","journal-title":"Int. J. Gynaecol. Obstet."},{"issue":"2","key":"10.1016\/j.ygyno.2024.02.002_bb0065","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.ygyno.2021.01.036","article-title":"Variations in incidence and mortality rates of endometrial cancer at the global, regional, and national levels, 1990-2019","volume":"161","author":"Gu","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2024.02.002_bb0070","doi-asserted-by":"crossref","unstructured":"N. Kayraklioglu, L. Katsakhyan, P.A. Cohen, N. Singh, J.T. Rabban, X. Matias-Guiu, Perceptions of controversies and unresolved issues in the 2014 FIGO staging system for endometrial cancer: survey results from members of the International Society of Gynecological Pathologists and International Gynecologic Cancer Society, Int. J. Gynecol. Pathol. (2023) Online ahead of print.","DOI":"10.1097\/PGP.0000000000000977"},{"key":"10.1016\/j.ygyno.2024.02.002_bb0075","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ygyno.2023.05.069","article-title":"The right time for change: a report on the heterogeneity of IVB endometrial cancer and improved risk-stratification provided by new 2023 FIGO staging criteria","volume":"175","author":"Haight","year":"2023","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2024.02.002_bb0080","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ygyno.2023.09.011","article-title":"Utility of the revised FIGO2023 staging with molecular classification in endometrial cancer","volume":"178","author":"Kobayashi-Kato","year":"2023","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2024.02.002_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113316","article-title":"Validation of the 2023 FIGO staging schema for advanced endometrial cancer","volume":"193","author":"Matsuo","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ygyno.2024.02.002_bb0090","article-title":"The 2023 FIGO staging system for endometrial carcinoma: predicted impact on stage distribution based on a retrospective analysis of 1169 cases","volume":"9900","author":"Schilling","year":"2023","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.ygyno.2024.02.002_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113317","article-title":"Verification of the prognostic precision of the new 2023 FIGO staging system in endometrial cancer patients - an international pooled analysis of three ESGO accredited centres","volume":"193","author":"Schwameis","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ygyno.2024.02.002_bb0100","doi-asserted-by":"crossref","first-page":"113318","DOI":"10.1016\/j.ejca.2023.113318","article-title":"New FIGO 2023 endometrial cancer staging validation. Welcome to the first molecular classifiers and new pathological variables!","volume":"193","author":"Vergote","year":"2023","journal-title":"Eur. J. Cancer"},{"issue":"16","key":"10.1016\/j.ygyno.2024.02.002_bb0105","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15164101","article-title":"Molecular classification of endometrial Cancer and the 2023 FIGO staging: exploring the challenges and opportunities for pathologists","volume":"15","author":"Zheng","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.ygyno.2024.02.002_bb0110","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/PAS.0000000000001020","article-title":"Molecular classification of grade 3 Endometrioid endometrial cancers identifies distinct prognostic subgroups","volume":"42","author":"Bosse","year":"2018","journal-title":"Am. J. Surg. Pathol."},{"issue":"2","key":"10.1016\/j.ygyno.2024.02.002_bb0115","doi-asserted-by":"crossref","first-page":"181","DOI":"10.6004\/jnccn.2023.0006","article-title":"Uterine neoplasms, version 1.2023, NCCN clinical practice guidelines in oncology","volume":"21","author":"Abu-Rustum","year":"2023","journal-title":"J. Natl. Compr. Cancer Netw."},{"issue":"3","key":"10.1016\/j.ygyno.2024.02.002_bb0120","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/PGP.0000000000000805","article-title":"Substantial Lymphovascular space invasion is an adverse prognostic factor in high-risk endometrial cancer","volume":"41","author":"Peters","year":"2022","journal-title":"Int. J. Gynecol. Pathol."},{"issue":"1","key":"10.1016\/j.ygyno.2024.02.002_bb0125","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ygyno.2011.09.017","article-title":"Lymphovascular space invasion is an independent risk factor for nodal disease and poor outcomes in endometrioid endometrial cancer","volume":"124","author":"Guntupalli","year":"2012","journal-title":"Gynecol. Oncol."},{"issue":"11","key":"10.1016\/j.ygyno.2024.02.002_bb0130","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1080\/0284186X.2019.1643036","article-title":"Lymphovascular space invasion as a predictive factor for lymph node metastases and survival in endometrioid endometrial cancer - a Swedish gynecologic cancer group (SweGCG) study","volume":"58","author":"Stalberg","year":"2019","journal-title":"Acta Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2024.02.002_bb0135","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.ygyno.2022.01.007","article-title":"Prognostic relevance of the molecular classification in high-grade endometrial cancer for patients staged by lymphadenectomy and without adjuvant treatment","volume":"164","author":"Leon-Castillo","year":"2022","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2024.02.002_bb0140","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.ygyno.2020.12.040","article-title":"The presence of an endometrioid component does not alter the clinicopathologic profile or survival of patients with uterine serous cancer: a gynecologic oncology group (GOG\/NRG) study of 934 women","volume":"160","author":"Hagemann","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2024.02.002_bb0145","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ygyno.2023.08.005","article-title":"Mixed clear cell\/endometrioid and clear cell\/serous carcinoma of the uterus are clinicopathologically similar to pure clear cell carcinoma: an NRG oncology\/gynecologic oncology group (GOG-210) study of 311 women","volume":"177","author":"Hagemann","year":"2023","journal-title":"Gynecol. Oncol."},{"issue":"Iss 1 Suppl 1","key":"10.1016\/j.ygyno.2024.02.002_bb0150","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1097\/PGP.0000000000000524","article-title":"Pathologic prognostic factors in endometrial carcinoma (other than tumor type and grade)","volume":"38 Suppl 1","author":"Singh","year":"2019","journal-title":"Int. J. Gynecol. Pathol."},{"issue":"1","key":"10.1016\/j.ygyno.2024.02.002_bb0155","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1136\/ijgc-2020-002230","article-title":"ESGO\/ESTRO\/ESP guidelines for the management of patients with endometrial carcinoma","volume":"31","author":"Concin","year":"2021","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"9","key":"10.1016\/j.ygyno.2024.02.002_bb0160","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.annonc.2022.05.009","article-title":"Endometrial cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Oaknin","year":"2022","journal-title":"Ann. Oncol."},{"issue":"10","key":"10.1016\/j.ygyno.2024.02.002_bb0165","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1038\/s41379-022-01102-x","article-title":"p53 immunohistochemistry in endometrial cancer: clinical and molecular correlates in the PORTEC-3 trial","volume":"35","author":"Vermij","year":"2022","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.ygyno.2024.02.002_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2023.10.034","article-title":"LBA40 phase III double-blind randomized placebo controlled trial of atezolizumab in combination with carboplatin and paclitaxel in women with advanced\/recurrent endometrial carcinoma","volume":"34","author":"Colombo","year":"2023","journal-title":"Ann. Oncol."},{"issue":"23","key":"10.1016\/j.ygyno.2024.02.002_bb0175","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa2302312","article-title":"Pembrolizumab plus chemotherapy in advanced endometrial Cancer","volume":"388","author":"Eskander","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"23","key":"10.1016\/j.ygyno.2024.02.002_bb0180","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1056\/NEJMoa2216334","article-title":"Dostarlimab for primary advanced or recurrent endometrial Cancer","volume":"388","author":"Mirza","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2024.02.002_bb0185","series-title":"WHO Classification of Tumours Female Genital Tumours","author":"Editorial Board WCoT","year":"2020"},{"issue":"6","key":"10.1016\/j.ygyno.2024.02.002_bb0190","doi-asserted-by":"crossref","first-page":"djv428","DOI":"10.1093\/jnci\/djv428","article-title":"Synchronous endometrial and ovarian carcinomas: evidence of Clonality","volume":"108","author":"Anglesio","year":"2016","journal-title":"J. Natl. Cancer Inst."},{"issue":"1","key":"10.1016\/j.ygyno.2024.02.002_bb0195","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1006\/gyno.1999.5415","article-title":"The significance of adnexal involvement in endometrial carcinoma","volume":"74","author":"Connell","year":"1999","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2024.02.002_bb0200","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1002\/ijc.32907","article-title":"Molecular profiling identifies synchronous endometrial and ovarian cancers as metastatic endometrial cancer with favorable clinical outcome","volume":"147","author":"Reijnen","year":"2020","journal-title":"Int. J. Cancer"},{"issue":"6","key":"10.1016\/j.ygyno.2024.02.002_bb0205","doi-asserted-by":"crossref","first-page":"djv427","DOI":"10.1093\/jnci\/djv427","article-title":"Massively parallel sequencing-based clonality analysis of synchronous endometrioid endometrial and ovarian carcinomas","volume":"108","author":"Schultheis","year":"2016","journal-title":"J. Natl. Cancer Inst."},{"issue":"Iss 1 Suppl 1","key":"10.1016\/j.ygyno.2024.02.002_bb0210","doi-asserted-by":"crossref","first-page":"S75","DOI":"10.1097\/PGP.0000000000000553","article-title":"Guidelines to aid in the distinction of endometrial and Endocervical carcinomas, and the distinction of independent primary carcinomas of the endometrium and adnexa from metastatic spread between these and other sites","volume":"38 Suppl 1","author":"Stewart","year":"2019","journal-title":"Int. J. Gynecol. Pathol."},{"issue":"5","key":"10.1016\/j.ygyno.2024.02.002_bb0215","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1002\/jso.26102","article-title":"Prognostic value of different metastatic sites for patients with FIGO stage IVB endometrial cancer after surgery: a SEER database analysis","volume":"122","author":"Li","year":"2020","journal-title":"J. Surg. Oncol."},{"issue":"35","key":"10.1016\/j.ygyno.2024.02.002_bb0220","doi-asserted-by":"crossref","first-page":"5400","DOI":"10.1200\/JCO.22.02906","article-title":"Oral Selinexor as maintenance therapy after first-line chemotherapy for advanced or recurrent endometrial Cancer","volume":"41","author":"Vergote","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2024.02.002_bb0225","doi-asserted-by":"crossref","unstructured":"F. Meric-Bernstam, V. Makker, A. Oaknin, D.Y. Oh, S. Banerjee, A. Gonzalez-Martin, et al., Efficacy and safety of Trastuzumab Deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial, J. Clin. Oncol. 42 (1) (2024) 47-58 (JCO2302005).","DOI":"10.1200\/JCO.23.02005"},{"issue":"1","key":"10.1016\/j.ygyno.2024.02.002_bb0230","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1136\/ijgc-2022-004039","article-title":"Refining adjuvant treatment in endometrial cancer based on molecular features: the RAINBO clinical trial program","volume":"33","author":"Consortium RR","year":"2022","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"12","key":"10.1016\/j.ygyno.2024.02.002_bb0235","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1136\/ijgc-2020-001929","article-title":"PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer","volume":"30","author":"van den Heerik","year":"2020","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"5","key":"10.1016\/j.ygyno.2024.02.002_bb0240","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1136\/ijgc-2023-004289","article-title":"Improving endometrial cancer assessment by combining the new techniqUe of GENomic profiling with surgical extra uterIne disEase assessment (EUGENIE)","volume":"33","author":"Kasius","year":"2023","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2024.02.002_bb0245","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ygyno.2023.09.009","article-title":"TP53 mutation and abnormal p53 expression in endometrial cancer: associations with race and outcomes","volume":"178","author":"Whelan","year":"2023","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2024.02.002_bb0250","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ygyno.2017.12.009","article-title":"Racial disparities in molecular subtypes of endometrial cancer","volume":"149","author":"Dubil","year":"2018","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2024.02.002_bb0255","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ygyno.2023.04.010","article-title":"Cost-effectiveness analysis of tumor molecular testing in stage III endometrial cancer","volume":"173","author":"Orellana","year":"2023","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2024.02.002_bb0260","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3322\/caac.21388","article-title":"The eighth edition AJCC Cancer staging manual: continuing to build a bridge from a population-based to a more \u201cpersonalized\u201d approach to cancer staging","volume":"67","author":"Amin","year":"2017","journal-title":"CA Cancer J. Clin."},{"issue":"9","key":"10.1016\/j.ygyno.2024.02.002_bb0265","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.ejso.2019.07.006","article-title":"Corrigendum to \u201cStaging of oropharyngeal squamous cell carcinoma of the head and neck: Prognostic features and power of the 8th edition of the UICC staging manual\u201d [Eur. J. Surg. Oncol. 45 (6) (2019) 1046\u20131053]","volume":"45","author":"Beltz","year":"2019","journal-title":"Eur. J. Surg. Oncol."},{"key":"10.1016\/j.ygyno.2024.02.002_bb0270","series-title":"AJCC cancer staging manual. Eight edition \/ editor-in-chief, Mahul B. Amin, MD, FCAP; editors, Stephen B. Edge, MD, FACS and 16 others; Donna M. Gress, RHIT, CTR - Technical editor; Laura R. Meyer, CAPM - Managing editor","first-page":"1024","volume":"xvii","author":"Amin","year":"2017"},{"issue":"7","key":"10.1016\/j.ygyno.2024.02.002_bb0275","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1001\/jamadermatol.2019.0032","article-title":"Performance of the American joint committee on Cancer staging manual, 8th edition vs the Brigham and Women\u2019s Hospital tumor classification system for cutaneous squamous cell carcinoma","volume":"155","author":"Ruiz","year":"2019","journal-title":"JAMA Dermatol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825824000829?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825824000829?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T16:54:31Z","timestamp":1726246471000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825824000829"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":55,"alternative-id":["S0090825824000829"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2024.02.002","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"2023 FIGO staging system for endometrial cancer: The evolution of the revolution","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2024.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}